MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Relmada Therapeutics Operating Expenses 2011-2026 | RLMD
Annual Operating Expenses Relmada Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 104 M | 161 M | 126 M | 60.8 M | 12.7 M | 6.92 M | 7.22 M | 16.2 M | 17.1 M | 13 M | 46.1 K | 13.8 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 161 M | 13.8 K | 43.7 M |
Quarterly Operating Expenses Relmada Therapeutics
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.3 M | 10.2 M | - | 23 M | 18.8 M | 23 M | - | 22.7 M | 26 M | 28.2 M | - | 38.7 M | 45.5 M | 38.3 M | - | 42.7 M | 26.5 M | 22.4 M | - | 17.2 M | 12.8 M | 9.97 M | - | 3.71 M | 4.14 M | 3.71 M | 3.48 M | 2.41 M | 5.89 M | 2.41 M | 1.46 M | 981 K | 1.46 M | 981 K | 1.54 M | 1.62 M | 1.54 M | 1.62 M | 5.72 M | 4.63 M | 5.72 M | 4.63 M | 4.38 M | 3.72 M | -4.38 M | -3.72 M | -5.06 M | -482 K | 19.8 K | 14.5 K | 9.32 K | 5.05 K | 2.59 K | 2.02 K | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 45.5 M | -5.06 M | 9.76 M |
Operating Expenses of other stocks in the Drug manufacturers industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
197 M | $ 1.24 | 3.78 % | $ 133 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
154 M | $ 2.67 | -0.19 % | $ 1.41 B | Canada |
 |
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
213 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | USA |
 |
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
12.6 M | - | - | $ 36.6 M | USA |
 |
Emergent BioSolutions
EBS
|
558 M | $ 13.83 | -0.61 % | $ 708 M | USA |
 |
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
196 M | $ 21.43 | -0.35 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
107 M | $ 5.66 | - | $ 351 M | USA |
 |
Harrow Health
HROW
|
90.1 M | $ 49.66 | -2.63 % | $ 1.62 B | USA |
 |
China Pharma Holdings
CPHI
|
2.6 M | $ 1.35 | - | $ 23.6 M |  China |
 |
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
41.4 M | $ 1.71 | 1.52 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
4.96 B | $ 7.88 | -0.32 % | $ 2.88 B | Canada |
 |
Pacira BioSciences
PCRX
|
279 M | $ 26.29 | 1.12 % | $ 1.22 B | USA |
 |
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 4.9 | -5.59 % | $ 68.9 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
55.6 M | - | - | $ 193 M | Canada |
 |
Sundial Growers
SNDL
|
102 K | $ 1.66 | 0.62 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 3.83 | 2.41 % | $ 4.75 M | USA |
 |
Organogenesis Holdings
ORGO
|
368 M | $ 4.32 | 0.35 % | $ 569 M | USA |
 |
Aurora Cannabis
ACB
|
183 M | $ 4.29 | 1.06 % | $ 86.3 M | Canada |
 |
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | USA |
 |
Veru
VERU
|
44 M | $ 2.38 | 0.21 % | $ 321 M | USA |
 |
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
Perrigo Company plc
PRGO
|
1.43 B | $ 14.81 | 1.47 % | $ 2.03 B | USA |
 |
ProPhase Labs
PRPH
|
47.1 M | - | - | $ 5.07 M | USA |
 |
Rockwell Medical
RMTI
|
31.1 M | $ 0.98 | 3.13 % | $ 22.9 M | USA |
 |
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
28.9 M | $ 1.06 | -4.93 % | $ 4.57 M | USA |
 |
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
133 M | $ 9.38 | -0.53 % | $ 666 M | USA |
 |
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
130 M | $ 5.54 | -1.34 % | $ 226 M | USA |
 |
SCYNEXIS
SCYX
|
67.5 M | $ 0.65 | 1.86 % | $ 31.1 M | USA |
 |
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
1.52 B | $ 8.99 | - | $ 5.56 B | Canada |
 |
TherapeuticsMD
TXMD
|
9.82 M | $ 2.0 | -1.96 % | $ 20.9 M | USA |
 |
Viatris
VTRS
|
4.88 B | $ 12.4 | -0.48 % | $ 15 B | USA |
 |
Zomedica Corp.
ZOM
|
14.1 M | - | -0.21 % | $ 98 M | USA |